Official websites use. Share sensitive information only on official, secure websites. The use, distribution or reproduction in other forums is permitted, provided the original author s and the copyright owner s are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these terms. Cell-based cancer immunotherapy has achieved significant advancements, providing a source of hope for cancer patients.
Notwithstanding the considerable progress in cell-based immunotherapy, the persistently low response rates and the exorbitant costs associated with their implementation still present a formidable challenge in clinical settings. In the landscape of cell-based cancer immunotherapies, an uncharted territory involves Type 2 innate lymphoid cells ILC2s and interleukin IL which promotes ILC2 functionality, recognized for their inherent ability to enhance immune responses.
These recent insights may hold significant promise for ILC2 cell-based immunotherapy. Nevertheless, the prospect of adoptively transferring ILC2s to confer immune protection against tumors has yet to be investigated. Moreover, we find that post-adoptive transfer of ILC2s, the number of tumor infiltrating ILC2s is inversely proportional to tumor size. Our results underscore the heightened efficacy of adoptively transferred ILC2s compared to alternative approaches, revealing an approximately one hundred fifty-fold superiority on a cell-per-cell basis over CAR T-cells in the specific targeting and elimination of tumors within the same experimental model.
Overall, this study demonstrates the functional significance of ILC2s in cancer immunosurveillance and provides the proof of concept of the potential utility of ILC2 cell-based cancer immunotherapies. Keywords: cell-based cancer immunotherapy, type 2 innate lymphoid cells, ILC2, interleukin, adoptive cell transfer, tumor infiltrating lymphocytes, ILC2 heterogeneity, type-1 immunity of ILC2. The advent of cancer immunotherapies based on the demonstration that T Lymphocytes limit the growth of tumors has revolutionized the available treatment landscape for several malignancies 1.
